NAUT — Nautilus Biotechnology Share Price
0.000.00%
Last trade - 00:00- $85.45m
- -$53.36m
- 23
- 50
- 17
- 20
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.44 | ||
| Price to Tang. Book | 0.44 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -35.85% | ||
| Return on Equity | -30.93% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 2.88 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- December 1st, 2016
- Public Since
- August 7th, 2020
- No. of Shareholders
- 34
- No. of Employees
- 134
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 126,148,469
- Address
- 2701 Eastlake Ave East, SEATTLE, 98102
- Web
- https://www.nautilus.bio/
- Phone
- +1 2063332001
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for NAUT
Q2 2025 Nautilus Biotechnology Inc Earnings Release
Q3 2025 Nautilus Biotechnology Inc Earnings Release
Similar to NAUT
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Nautilus Biotechnology share price?
As of Today at 22:13 UTC, shares in Nautilus Biotechnology are trading at $0.68. This share price information is delayed by 15 minutes.
How has the Nautilus Biotechnology share price performed this year?
Shares in Nautilus Biotechnology last closed at $0.68 and the price had moved by -74.63% over the past 365 days. In terms of relative price strength the Nautilus Biotechnology share price has underperformed the S&P500 Index by -77.12% over the past year.
What are the analyst and broker recommendations for Nautilus Biotechnology?
The overall consensus recommendation for Nautilus Biotechnology is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Nautilus Biotechnology dividend yield?
Nautilus Biotechnology does not currently pay a dividend.
Does Nautilus Biotechnology pay a dividend?
Nautilus Biotechnology does not currently pay a dividend.
When does Nautilus Biotechnology next pay dividends?
Nautilus Biotechnology does not currently pay a dividend.
How do I buy Nautilus Biotechnology shares?
To buy shares in Nautilus Biotechnology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nautilus Biotechnology?
As of the previous close price of $0.68, shares in Nautilus Biotechnology had a market capitalisation of $85.45m.
Where are Nautilus Biotechnology shares listed?
Here are the trading details for Nautilus Biotechnology:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: NAUT
What kind of share is Nautilus Biotechnology?
Based on an overall assessment of its quality, value and momentum Nautilus Biotechnology is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nautilus Biotechnology share price forecast for 2025?
The analyst consensus target price for shares in Nautilus Biotechnology is $1.75. That is 158.34% above the last closing price of $0.68.
Analysts covering Nautilus Biotechnology currently have a consensus Earnings Per Share (EPS) forecast of -$0.57 for the next financial year.
Find out moreWhat is the trend in the Nautilus Biotechnology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nautilus Biotechnology. Over the past six months, its share price has underperformed the S&P500 Index by -73.93%.
As of the last closing price of $0.68, shares in Nautilus Biotechnology were trading -66.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nautilus Biotechnology PE Ratio?
The Nautilus Biotechnology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.68.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nautilus Biotechnology?
We do not have data on Nautilus Biotechnology's directors